Table 1.
Summary of 5 Dengue Serosurveys in Singapore, 2004–2017
| Survey | Agency or Institution | Age Range, years | Sample Size (n) | Survey Period | ELISA Testa | Source (First Author, Year (Reference No.)) |
|---|---|---|---|---|---|---|
| National Health Surveyb | MOH | 18–74 | 4,152 | September–December 2004 | Panbio Dengue IgG Indirect ELISAc | Yew, 2009 (24) |
| National Paediatric Seroprevalence Surveyb | MOH | 2–15 | 984 | August 2008–July 2010 | EUROIMMUN Anti-Dengue Virus ELISA (IgG)d | Ang, 2015 (25) |
| 2009 seroprevalence surveyb | NEA/EHI | 16–60 | 3,627 | December 2009–February 2010 | Panbio Dengue IgG Indirect ELISA | Low, 2015 (21) |
| 2013 seroprevalence survey | NEA/EHI | 16–71 | 3,813 | December 2013–February 2014 | Panbio Dengue IgG Indirect ELISA | Present study |
| 2017 seroprevalence survey | NEA/EHI | 16–74 | 4,002 | June–August 2017 | Panbio Dengue IgG Indirect ELISA | Present study |
Abbreviations: EHI, Environmental Health Institute; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; MOH, Ministry of Health; NEA, National Environment Agency.
a The sensitivity (Panbio: 97.9%; EUROIMMUN: 100%) and specificity (Panbio: 100%; EUROIMMUN: 100%) of the Panbio and EUROIMMUN assays (as provided in the product inserts) were similar. Both assays were tested in a serum sample panel of patients with suspected dengue virus infection (n = 87), and the qualitative results of the two ELISAs were 99% in agreement (EUROIMMUN Anti-Dengue Virus ELISA (IgG) product information). This shows that the data from these studies may be used collectively for analysis. The total number of samples analyzed in these 5 studies was 16,578.
b A brief description of prior studies can be found in Web Appendix 1.
c Alere Inc., Waltham, Massachusetts.
d EUROIMMUN AG, Lübeck, Germany.